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Iron Deficiency Anemia
Heather Weaver RN
Introduction
What is Iron Deficiency 
Anemia (IDA)?
“Iron deficiency anemia is the most common type of 
nutritional disorder worldwide, occurring in both developing 
and developed countries and affecting as many as one-fifth 
of the world population” (Huether & McCance, 2018, p. 934). 
It is characterized as a microcytic-hypochromic anemia 
(which will be discussed in more detail in the Underlying 
Pathophysiological section). The American Society of 
Hematology (2019) reports iron is important in the 
production of hemoglobin and maintenance of healthy cells. 
It is estimated that IDK affects 2-6% of men and 
postmenopausal women and an astounding 10-15% women 
during childbearing age world wide (Calaf, Estadella, Feliu, 
Perelló, & Villamarín, 2018).
Pathophysiological Process
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Why is IDA Important to the 
Advanced Practice Nurse?
It is very likely as an advanced practice nurse (APN) that  
medical care will be provided to patients with IDA. The APN 
will need to have a strong understand of the signs and 
symptoms of IDA. As well as, the pathophysiology and 
treatment options. The ability of the APN to diagnose and 
treat IDA is imperative because it is associated with increase 
morbidity and mortality. “ For example, IDA may cause 
permanent cognitive impairment in children, fatigue or hear 
failure in adults, and serious maternal and fetal 
complications: (Cadet, 2018, p. 108).
Most Common Signs and Symptoms of 
IDA
Signs (Objective Findings):
§ Pale colored skin (especially in eyelids, tongue/mucous membranes, and 
palmar aspect of hands)
§ Brittle nails
§ Normal blood pressure (BP) in early or compensated stages and 
hypotension in late or uncompensated stages
§ Tachycardia
§ Tachypnea
§ Altered mental status (AMS) or changes in the level of consciousness 
(LOC)
§ Dysrhythmias (severe cases)
Symptoms (Subjective Finding/Patient Reported):
§ May be asymptomatic (usually in the beginning stages)
§ Fatigue/weakness
§ Dizziness/lightheadedness
§ Shortness of breath/dyspnea (especially on exertion)
§ Palpitations
§ Angina
§ Headache
Conclusion
In conclusion, IDA is the most common blood disorder worldwide in 
both developing and devolved countries. It is more common in women 
during child childbearing years and children, though it does affect men as 
well. IDA can be caused by a wide range of conditions, and it is important 
for APN to obtain a thorough PMI and HPI and perform a detailed 
assessment to look for the signs and symptoms of IDA. Correction of the 
cause, dietary changes, and iron replacement, either oral or parental is the
the common treatment plan. Severe cases my require blood transfusion 
and hospitalization. 
Underlying Pathophysiology
§ IDK is characterized as microcytic-hypochromic anemia  (see figure 1.) 
which can be defined as “abnormally  small erythrocytes that contain 
unusually reduced amounts of hemoglobin” (Huether & McCance, 2018, P. 
934)
§ ”Apart from its well-known function of an oxygen carrier in hemoglobin 
and myoglobin, iron is required for the efficient functioning of numerous 
other heme and non-heme enzymes” (Harmse, 2016).
§ “Each hemoglobin molecule is compose of two pairs of polypeptide chains 
(the globins) and four colorful complexes of iron plus protoporphyrin (the 
hemes) responsible for the ruby-red color and oxygen carrying capacity” 
(Huether & McCance, 2018, p. 906). Therefore, when iron levels are low 
the body is unable to properly produce hemoglobin in the amounts 
necessary to create sufficient erythrocytes. This is what causes the signs 
and symptoms of IDA.
§ Under normal functions iron is recycled when RBC are engulfed by 
macrophages; the body then stores the iron as ferritin and hemosiderin in 
the liver, bone marrow, skeletal muscles, spleen and duodenum (Harmse, 
2016). When iron levels are low the body cannot keep up with the 
absorption and iron stores will eventually be depleted. 
§ Chronic inflammation causes increased production of hepcidin (iron 
regulatory hormone) which will decrease iron absorption in the GI tract 
(Harmse, 2016). Often times, non-steroidal anti-inflammatory NSAIDs) 
medications are prescribed for chronic inflammation which can increase a 
patient’s risks for GI bleeding and worsen IDA.
According to Huether and McCance (2018)  IDA can be broken down into three 
stages:
§ In stage I, the body’s iron stores are depleted. Erythropoiesis proceeds 
normally, with the hemoglobin content or erythrocytes remaining normal.
§ In stage II, iron transportation to bone marrow is diminished, resulting in 
iron-deficient erythropoiesis.
§ Stage III begins when  when the small hemoglobin-deficient cells enter the 
circulation to replace the normal aged erythrocytes that have been 
removed from the circulation. 
§ The manifestation of IDA appear in stage III when there is depletion of iron 
stores and diminished hemoglobin production. (p. 935)
Figure 1. Demonstrates the changes in erythrocytes in IDA. A)
normal erythrocytes. B) microcytic-hypochromic erythrocytes 
(Kamran & Warner, 2018).
A B
Etiology
IDA has a wide variety of causes and it is important for the 
APN to take careful consideration of the patients history 
when determining the cause and treatment plan. Huether 
and McCance (2018) identify the causes of IDA as “(1) dietary 
deficiency, (2) impaired absorption, (3) increased 
requirements, and (4) chronic blood loss. 
1) Dietary deficiency
§ Dietary intake low in iron
§ Children age 12-26 months as a result of prolonged 
breast feeding without iron supplement (Buchanan & 
Powers, 2017)
2) Impaired absorption
§ Diets high in dairy
§ Helicobacter pylori (H. pylori) gastrointestinal (GI) 
infections (Cadet, 2018)
§ Bariatric procedures, especially gastric bypass surgery 
(American Society of Hematology, 2019)
§ Proton Pump Inhibitors (PPI) use (Harmse, 2016)
§ Chronic inflammatory disease
3) Increased requirements
§ Pregnancy
§ Growing infants, children, and adolescents (Huether & 
McCance 2018) 
4) Chronic blood loss
§ Menorrhagia
§ Occult bleeding from ulcerative colitis, Crohn’s disease, 
esophagitis, cancer of the bowels, hemorrhoids, and 
gastric/duodenal ulcers (Jones & Peate, 2014)  
§ Microscopic bleeding from the urinary tract (renal or 
bladder)
Figure 2. Flow diagram outlining the management of an iron 
deficient patient (Harmse, (2016).
Presentation of Case
Mr. Smith is a 51 year old, African-American male that presents with fatigue, 
occasional exertional shortness of breath, abdominal cramping, and intermittent 
headaches for the past 3 weeks. He has no known drug allergies (NKDA) and his 
only past medical history is ulcerative colitis (UC). He has smoked ½ pack of
cigarettes per day for the past 30 years. During physical examination it is noted that 
his his skin color is normal but his oral mucosa and nail beds are pale and his nails 
are brittle. He is normotensive, his heart rate is 103 beats per minute (BPM) and his 
oxygen saturation is 97%. After further testing the following abnormal results were
found for Mr. Smith: Guaiac positive, red blood cells (RBC) count is 2.9 M/mcl, 
hemoglobin is 8.1 g/dl, hematocrit is 26.1%, iron 21.6 mcg/dL, and ferritin 9.6 ng/ml. 
Mr. Smith is started on an oral iron supplement and instruction to take it 1 hour 
before or 2 hours after a meal with water or juice (not with dairy products). He is 
also prescribed a corticosteroid for the UC. He is referred to a gastroenterologist for 
a esophagogastroduodenoscopy (EGD) and colonoscopy. His is also given and  order 
to have repeat lab work ordered in one month. He is encouraged to stop smoking 
and given the signs and symptoms that would mandate him to go to the emergency 
department. 
Significance of Pathophysiology Assessment and Treatment Options
§ When IDA is first diagnosed it is essential that the cause is found in order 
to best treat the condition properly. 
§ A complete history of presenting illness (HPI) and past medical history 
(PMI) must be obtained.
§ A thorough physical assessment must performed to find the signs and 
symptoms of IDA.
§ A complete blood count (CBC) will need to be ordered. Pay special 
attention to the red blood cells (RBC); hemoglobin (Hgb); hematocrit, 
mean corpuscular volume (MCV) RBC size;  mean corpuscular hemoglobin 
(MCH) average mass of Hgb per RBC; mean corpuscular hemoglobin 
concentration (MCHC) average concentration of Hgb per a single RBC; and 
red cell distribution width (RDW) show variation of the RBC size and 
volume. (Cadet, 2018).
§ Labs pertaining specifically to iron include: iron levels, total iron-binding 
capacity (TIBC), iron saturation, and ferritin.
§ It is recommended to start by increasing foods rich in iron which include: 
meats (especially organ meats such as liver), poultry, fish, leafy green 
vegetables, legumes, dried fruits, and iron-enriched grain products 
(American Society of Hematology, 2019). 
§ “The first-line treatment for IDA is oral iron replacement therapy (e.g. 
ferrous sulfate, ferrous gluconate, ferrous fumarate) for 3-6 months for 
iron stores repletion” (Cadet, 2018, p. 109).
§ Ferrous sulfate is most often the preferred iron salts replacement therapy 
for IDA treatment. 
§ “Intravenous iron administration, in some cases accompanied by 
erythropoietic agents, is recommended in patients with intestinal 
malabsorption, intolerance to oral iron supplement, severe anemia, or in 
those requiring rapid iron recovery (Calaf et al., 2018, p. 41). 
§ Lastly, blood transfusions with appropriately typed and screened RBCs my
be necessary for Hgb below 7 g/dL or those who are extremely 
symptomatic.
With the prevalence of IDA being so high it is important that APNs are vigilant 
in identifying the signs and symptoms of IDA early. APN must have a strong 
understanding of the etiology, pathophysiology, and treatment of IDA. As 
previously mentioned, it is estimated that IDK affects 2-6% of men and 
postmenopausal women and 10-15% women during childbearing age world wide 
(Calaf et al., 2018). Often times, the signs and symptoms of IDA can be vague and 
mimic other disorders or disease processes, which can delay the diagnosis. As
identified in the previous section, IDA  symptoms don’t generally present until 
stage III,  after the pathological process has been occurring for sometime. Late 
detection can lead to worsening symptoms, comorbidities, and mortality. This is 
especially concerning in patients that are young children, non-verbal, and 
normally confused, as they will not be able to provide the APN with presenting 
symptoms.
The Center for Disease Control and Prevention (CDC) (2017) list the following 
statistics for IDA in the year of 2017:
§ 2.8  million out-patient office visits with IDA/anemia as the primary 
diagnosis
§ 526,000 visits to the emergency department where IDA was the primary 
diagnosis
§ 5,382 number of deaths caused by IDA 
